Waddell & Reed Financial’s Amedisys AMED Stock Holding History

Waddell & Reed Financial’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-70,500	Closed	-$4.43M	–	523
2017 Q2	$4.43M	Buy	+70,500	New	+$4.11M	0.01%	487

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Waddell & Reed Financial's AMED Position: Q3 2017 in Review

Waddell & Reed Financial sold out of Amedisys (AMED) in Q3 2017, closing a stake of 70,500 shares — an estimated $4.43M sold.

Waddell & Reed Financial first reported a position in AMED in Q2 2017 and held it in 1 quarter. The position peaked at $4.43M in Q2 2017. 163 funds tracked by Wall St. Rank hold AMED as of Q3 2017.

Waddell & Reed Financial reported no remaining Amedisys position as of Q3 2017 after selling out during the quarter.
Waddell & Reed Financial sold 70,500 Amedisys shares in Q3 2017, an estimated $4.43M.
Waddell & Reed Financial first reported a position in Amedisys in Q2 2017 and held it in 1 quarter.
Waddell & Reed Financial's Amedisys position peaked at $4.43M in Q2 2017.
163 funds tracked by Wall St. Rank held Amedisys as of Q3 2017.

Based on Waddell & Reed Financial's 13F filing for Q3 2017, filed 14 Nov 2017.